An observational study in Kidney Cancers, Bladder Cancer and Prostate Cancer, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by University Hospital, Strasbourg, France · Observational
Among 108 studies in Kidney Neoplasms with a site in France — 31 open to participants now, 36 under way, 4 of them phase 3. Kidney Neoplasms · France.
Among the 108 studies in Kidney Neoplasms with a site in France, this one is the 19th largest by planned enrollment of the 30 observational ones, is one of 4 that started in 2024, is one of 30 observational ones, reaches primary completion later than 29 of the 35 other live ones, and was the 105th registered.
969 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.
This study's planned enrollment of 100 is below the median of 211 across 215 observational studies indexed under Kidney Neoplasms.
Browse Kidney Neoplasms studies →31 of the 108 studies in Kidney Neoplasms with a site in France are open now, in 12 countries. Each count lists the studies.
Of the 173 Kidney Neoplasms studies recruiting now, 133 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →108 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 4 started in 2024.
Median enrollment 100 across the 78 interventional studies, 163 across the 30 observational. Of the 58 that completed or were terminated, 17 (29%) have results posted.
34 of 108 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.
University Hospital, Strasbourg, France has 5 studies filed under Kidney Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Kidney Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03185039Institut Paoli-CalmettesPredictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents | 2026-12-19 |
| NCT07739121Assistance Publique - Hôpitaux de ParisBenchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations | 2026-12-31 |
| NCT06026410Kura Oncology, Inc.KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | 2027-01 |
| NCT05433142Xencor, Inc.Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | 2027-02 |
| NCT05241561Centre Hospitalier Universitaire de BesanconCabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients | 2027-03 |
Among the 108 studies in Kidney Neoplasms with a site in France, from their registry updates:
This is a study :
The main objective is to establish and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells.
Translated with DeepL.com (free version)
Inclusion Criteria:
Inclusion criteria:
Criteria common to all patients:
Specific criteria for patients with renal cell carcinoma (RCC):
Or
- Partial nephrectomy (PN): with tumors at stage T2 or T3a)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An additional 10 ml blood sample taken during a routine blood test
Constitute and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells.
For the establishment of the models, it is necessary to have: sufficient cell viability after enzymatic dissociation of the tissues and a correspondence of patient/model 3D therapeutic responses. The patients' blood will be collected to isolate immune cells using a Ficoll gradient, to integrate them into the forming 3D structures, taking into account the proportion present in the primary tumor tissues of each patient, for the 3D structures developed from their tumor.
Time frame: Day 1 after surgery
Started Sep 2024 (actual). Primary completion is estimated for Sep 2029, 60 months after the start.
Of 89 non-industry observational studies under Kidney Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34. This study's planned 60 months is below that.
Counting every sponsor, half of 107 studies reached it within 74 months; a quarter within 28.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →